Hims & Hers Health CEO Andrew Dudum said the company will continue to sell cheap weight-loss shots despite Novo Nordisk A/S ...

Despite Novo Nordisk (NVO) recently ending a partnership with Hims & Hers Health (NYSE:HIMS) to distribute its weight-loss ...

Hims & Hers lost a valuable collaboration with Novo Nordisk over compounded GLP-1s. Could it hurt the company's potential to ...

Hims & Hers Health HIMS. After $NVO Novo Nordisk abruptly terminated their partnership, citing "deceptive marketing," Hims & Hers fired back with confidence… saying they'll cont ...

Novo Nordisk has cut ties with Hims & Hers Health, alleging that the latter company has engaged in deceptive marketing ...

Shell (NYSE:SHEL) has denied a report that it is in talks to acquire oil rival BP (NYSE:BP). “This is further market ...

In this week’s edition of InnovationRx, we look at health insurers' vows to improve prior authorization, Bell Labs’ IP ...

2025年6月24日， Hims & Hers Health（HIMS）披露1笔公司内部人交易情况。高管Okupe Oluyemi于2025年6月23日卖出2.31万股。 Hims & Hers Health, ...

Novo Nordisk had been providing Hims & Hers with the FDA-approved Wegovy, an injectable semaglutide used for weight loss ...

Hims & Hers一直依赖复方制剂业务 —— 该业务去年占其收入的 15%—— 作为向投资者推介的增长故事的一部分。该公司指控诺和诺德强迫其 “引导” 患者使用品牌药 Wegovy，而诺和诺德则指控Hims & Hers引导患者使用未经批准的复方或 “仿冒” 药物。 Hims & Hers首席执行官安德鲁・杜杜姆（Andrew Dudum）在社交平台 X 上发帖称：“最近几周，诺和诺德的商业团 ...

Andrew Stanton is a Newsweek weekend reporter based in Maine. His role is reporting on U.S. politics and social issues. Andrew joined Newsweek in 2021 from The Boston Globe. He is a graduate of ...

Zacks.com users have recently been watching Hims & Hers Health (HIMS) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.